Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Sociedad Venezolana de Farmacología Clínica y Terapéutica
2004
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=55923104 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Pamidronato en la enfermedad metastásica ósea MD Ventín C León Medicina Cancer Metastasis Pamidronate Bony markers Quality of life The bony metastasis is a common complication of many cancer types. These predispose to the development of: pain, pathological fractures and hypercalcaemia, that reduce the quality of the patients life. Evidence of bony destruction increased in the illness metastasic exists. The biphosphonates like the Pamidronate, inhibit the activity osteoclastic and reduce the bony reasorption. Methods: Patient with bony metastasis determined by gammagrama, received Pamidronate endovenous (90 or 60 mg) or placebo, markers of bony reasorption and quality of life were evaluated before the treatment and through the study. Results: The level of calcium plasmatic and calcium urinary of 24 hours it didnt vary in any group. The alkaline fosfatase descended not significantly in the treatment groups. The corrected DPD (cross-linked: Piridoline y Deoxipiridoline colagen), diminished not significantly in the groups. In the subscale of physical well-being clinical improvement was observed in the group of 90 mg (p 0,05). Conclusions: The monthly infusions of Pamidronate, improve the bony pain in patient with bony metastasis 2004 artículo científico 0798-0264 https://www.redalyc.org/articulo.oa?id=55923104 en http://www.redalyc.org/revista.oa?id=559 Archivos Venezolanos de Farmacología y Terapéutica application/pdf Sociedad Venezolana de Farmacología Clínica y Terapéutica Archivos Venezolanos de Farmacología y Terapéutica (República Bolivariana de Venezuela) Num.1 Vol.23